Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 23 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/20/2008 First Published: 10/21/2005


1.		Phase II/III Randomized Study of Paclitaxel and Carboplatin With Versus Without AZD2171 in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				Other, Pharmaceutical / Industry				CAN-NCIC-BR24 ZENECA-CAN-NCIC-BR24, NCT00245154, BR24, FHCRC-6107, UWCC-UW 6107, UWCC- 06-2707-H/B


2.		Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Temporarily closed				18 and over				Pharmaceutical / Industry				D8480C00040 NCT00539331

Last Modified: 5/23/2007 First Published: 10/21/2005


3.		Phase II Study of AZD2171 in Patients With Refractory Stage IV Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				DFCI-05160 7099, NCI-7099, NCT00244881

Last Modified: 11/16/2007 First Published: 9/23/2005


4.		Phase II Study of AZD2171 in Patients With Progressive Unresectable, Locally Recurrent or Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				PMH-PHL-039 7128, NCI-7128, NCT00227760

Last Modified: 4/24/2008 First Published: 10/7/2005


5.		Phase II Study of AZD2171 in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				NCCTG-N044J N044J, NCT00238394

Last Modified: 3/19/2008 First Published: 10/14/2005


6.		Phase II Study of AZD2171 in Patients With Unresectable Malignant Pleural Mesothelioma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-S0509 S0509, NCT00243074

Last Modified: 7/25/2008 First Published: 10/21/2005


7.		Phase II Study of AZD2171 in Patients With Recurrent Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCC-PHII-64 NCI-7097, 7097, NCT00245063

Last Modified: 7/28/2008 First Published: 1/13/2006


8.		Phase II Study of AZD2171 in Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				PMH-PHL-037 7129, NCI-7129, NCT00278343

Last Modified: 7/5/2007 First Published: 3/17/2006


9.		Phase II Study of AZD2171 in Patients With Recurrent Glioblastoma Multiforme

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				NCI				MGH-05-254 NCI-7105, 7105, NCT00305656

Last Modified: 9/6/2007 First Published: 3/13/2006


10.		Phase II Study of AZD2171 in Patients With Refractory Metastatic Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				UCCRC-NCI-7111 7111, NCI-7111, NCT00303862

Select All on One Page


					1 2 3 Next >

| | | | | | | |

A Service of the National Cancer Institute